Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Muscle Invasive Bladder Cancer 1Lung Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Metastatic Breast Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 25Cisplatin 20Carboplatin 14Paclitaxel 11Radiotherapy 9Radiotherapy, Intensity-Modulated 8Docetaxel 8Cetuximab 8Nivolumab 7cemiplimab 5Radiation 5durvalumab 4atezolizumab 3Taxes 3Surveys and Questionnaires 3Fluorouracil 3Drug Therapy 3Cyclophosphamide 3Blood Specimen Collection 3toripalimab 2olaparib 2fludarabine 2avelumab 2alpha-2'-deoxythioguanosine 2aldesleukin 2Surgical Procedures, Operative 2Standard of Care 2Pemetrexed 2Magnetic Resonance Spectroscopy 2vistusertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Squamous Cell × vistusertib × 1 year × Clear all
NCT02664935 2026-04-28

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

University of Birmingham

Phase 2 Completed
423 enrolled
Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡